| Identification | Back Directory | [Name]
(2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide | [CAS]
2101517-69-3 | [Synonyms]
BL 918 NEW
BL-918
(BL918)
(2R)-2-({[3,5-bis(trifluoromethyl)phenyl]carbamothioyl}amino)-N-(2,4-difluorophenyl)-2-phenylacetamide | [EINECS(EC#)]
825-946-9 | [Molecular Formula]
C23H15F8N3OS | [MDL Number]
MFCD31693829 | [MOL File]
2101517-69-3.mol | [Molecular Weight]
533.437 |
| Questions And Answer | Back Directory | [Uses]
BL 918 is a potent small-molecule activator of UNC-51-like kinase 1 (ULK1), a serine-threonine kinase involved in autophagy. Promotes cytoprotective autophagy in MPP+-treated SH-SY5Y cells, via the ULK complex. Improves motor dysfunction and reduces loss of dopaminergic neurons, mediated by MPTP, in in vivo models of Parkinson’s disease. |
| Chemical Properties | Back Directory | [density ]
1.508±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 250 mg/mL (468.66 mM) | [form ]
A solid | [pka]
11.13±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [in vivo]
BL-918 (compound 33i; 20, 40, or 80 mg/kg/day; oral gavage; began 2 days before the first injection of saline/MPTP and continuously maintained for 5 days after the last injection of saline/MPTP) attenuates the loss of DA and its metabolites. BL-918 obviously decreases the levels of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA)[1].
| Animal Model: | Male C57BL/6 mice (eight-week old) weighing between 20 and 25 g[1] | | Dosage: | 20, 40, or 80 mg/kg | | Administration: | Oral gavage; daily; began 2 days before the first injection of saline/MPTP and continuously maintained for 5 days after the last injection of saline/MPTP | | Result: | Attenuated the loss of DA and its metabolites.
|
| [IC 50]
ULK1: 24.14 nM (EC50); ULK1: 0.719 μM (Kd) |
|
|